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Enzymatic transhalogenation of dendritic RGD
peptide constructs with the ﬂuorinase†
Stephen Thompson,a Ian N. Flemingb and David O’Hagan*a
The substrate scope of ﬂuorinase enzyme mediated transhalogenation reactions is extended. Substrate
tolerance allows a peptide cargo to be tethered to a 5’-chloro-5’-deoxynucleoside substrate for trans-
halogenation by the enzyme to a 5’-ﬂuoro-5’-deoxynucleoside. The reaction is successfully extended from
that previously reported for a monomeric cyclic peptide (cRGD) to cargoes of dendritic scaﬀolds carrying
two and four cyclic peptide motifs. The RGD peptide sequence is known to bind upregulated αVβ3 integrin
motifs on the surface of cancer cells and it is demonstrated that the ﬂuorinated products have a higher
aﬃnity to αVβ3 integrin than their monomeric counterparts. Extending the strategy to radiolabelling of the
peptide cargoes by tagging the peptides with [18F]ﬂuoride was only moderately successful due to the
poor water solubility of these higher order peptide scaﬀolds although the strategy holds promise for
peptide constructs with improved solubility.
1. Introduction
The fluorinase enzyme (E.C. 2.5.1.63) was originally isolated1
from the soil bacterium Streptomyces cattleya and has recently
been identified in a number of other bacterial species.2 The
enzyme shows promise as a biocatalyst for the incorporation of
fluorine-18 into [18F]-labelled PET radiotracers, and has the
singular attribute that the C–F bond forming reaction is
carried out under neutral aqueous conditions.3–6 The fluori-
nase catalyses the combination of fluoride ion and S-adenosyl-
L-methionine 1 (SAM) to generate 5′-fluoro-5′-deoxyadenosine 2
(FDA) and L-(S)-methionine 3 (L-Met) (Scheme 1A).1,7 We have
recently demonstrated that the enzyme has a specificity toler-
ance at the 2-position of the adenine base.5 Replacement of
hydrogen with an acetylene group at this position, as shown in
Scheme 1B, gave the modified substrate ClDEA 4 which was an
eﬃcient substrate for transhalogenation in the presence of
Se-adenosyl-L-selenomethionine (SeSAM).7 This transformation
was utilised to prepare [18F]FDEA [18F]-6 under ambient
aqueous conditions. The pendant acetylene moiety was then
eﬃciently reacted with an azido-cRGD (cyclic arginyl-glycinyl-
aspartyl) peptide using the CuAAC (Cu-catalysed alkyne–azide
cycloaddition) click reaction, to generate a [18F]-radiolabelled
cRGD construct.6
While two step strategies involving prosthetic groups
remain widely used for radiolabelling of peptides and proteins
with fluorine-18,8 it is attractive to consider the development
of straightforward, “last step” radiolabelling protocols. Such
protocols need to be relatively rapid due to the short half-life
of fluorine-18 (t1/2 = 109.7 min), and be conducted under con-
ditions that preserve the structural and functional integrity of
the biomolecule.9 The poor nucleophilicity of aqueous [18F]flu-
oride ion, the form most readily prepared on a cyclotron with
an [18O]H2O target,
10 often precludes direct labelling of bio-
molecules using a “last step” approach. To circumvent the
limited reactivity of aqueous [18F]fluoride, fluoride sequester-
ing strategies have been explored. For example boron,11 alu-
minium12 and silicon13 based methods have been developed
in an eﬀort to achieve “last step” radiolabelling of peptides by
bioconjugation approaches which secure these elements to the
peptide in advance. The strategies have proven successful and
these technologies are being further developed,14,15 but there
are challenges as the conditions required to achieve fluoride
ion sequestration require various combinations of low pH,
organic solvents and heating. The fluorinase has the capacity
to catalyse C–F bond formation at ambient temperature and
near neutral pH. Within this context, we have previously
demonstrated5 a fluorinase enzyme-based system for “last
step” radiolabelling of a small cRGD peptide 7. The peptide
was tethered to a 5′-chloro-5′-deoxynucleoside substrate
through a PEG linker prior to enzymatic radiolabelling with
[18F]fluoride, as shown in Scheme 1B. This proved successful
and the radiolabelled construct [18F]-8 was shown to be stable
to defluorination in vivo (in a rat), and the cRGD moiety
retained high aﬃnity for αVβ3 integrins. In order to explore
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this approach further, we wished to examine whether the sub-
strate scope at the C-2 position would extend to larger, more
complex peptides.
The search for high aﬃnity ligands for biological receptors
has led to the development of imaging agents based on multi-
valent antibody fragments16 or multivalent small peptides.17
Multimeric interactions play a key role in recognition events
between biological ligands and receptors.18 Weak non-covalent
interactions between monovalent ligands and individual recep-
tors can be enhanced by attaching multiple ligands to a single
scaﬀold.19,20 Incorporating the RGD (arginyl–glycinyl–aspartyl)
tripeptide motif into cyclic pentapeptides gives cRGDs, a class
of high aﬃnity ligands for αVβ3 integrin, a cell surface protein
identified as a biomarker of angiogenesis and strongly associ-
ated with malignant tumours.21,22 Multimeric cRGD peptides
are validated constructs employed for PET imaging using
either fluorine-18 or heavy metal PET isotopes.19,23,24 Usually
the cRGD peptide is conjugated to a metal chelating group for
Scheme 1 A. The native reaction catalysed by the ﬂuorinase enzyme. B. Fluorinase catalysed transhalogenation reactions with C-2 modiﬁed
substrates.
Scheme 2 Synthesis of protected aldehyde 11 and amine 14 for reductive amination to generate the desired alkynyl frameworks 15 and 16.
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co-ordination to radiometals, often at the final step in the syn-
thesis of such a tracer. Fewer fluorine-18-based multivalent
radiotracers have been developed, as incorporation of fluorine-
18 into such scaﬀolds often requires a multi-step, prosthetic
group-based strategy.25–28 However, two multimeric cRGD-
based radiotracers have been reported recently, synthesised
using a “last step” radiofluorination protocol. These are the
aluminium chelates, [18F]alfatide I14,29 and [18F]alfatide II15,30
which were prepared using a kit-like31 methodology and they
have been evaluated in humans.14,15 In addition, the CuAAC
reaction between an alkyne and an azide-modified cRGD
peptide has also proved useful for the assembly of multimeric
cRGD peptides, which were subsequently labelled with
radiometals.32–35
Herein, we report our initial results on “last step” fluorina-
tion of structurally complex multimeric cRGD peptides with
the fluorinase enzyme. A primary objective at this stage was to
establish if the fluorinase could tolerate higher molecular
weight cargoes attached to the C-2 position of the adenine
base. Although successful biotransformations could be
achieved with fluoride, it became apparent that reduced solu-
bility of higher molecular weight substrates proved challenging
for eﬃcient radiolabelled experiments, where the fluoride-18
concentrations are necessarily low.
2. Results and discussion
2.1. Synthesis of di- and tetra-alkynes for a CuAAC reaction
A multimeric peptide substrate for the fluorinase requires an
enzyme recognition/reaction site attached to a linker to extend
the peptide cargo away from the surface of the enzyme.
In order to assemble such a substrate, we envisaged a strategy
Scheme 3 Synthesis of halogenated 2-iodo coupling partners 18 and
20 for Sonogashira coupling.
Scheme 4 Synthesis of pendant di- and tetra-acetylene cores attached to 5’-halo-5’deoxyadenosine motifs.
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similar to that used for the synthesis of 5 and 7 (Scheme 1B).5
A Sonogashira coupling was identified for coupling a 2-iodo-
nucleoside to an alkynyl-PEG linker, which had been pre-
functionalised with either a protected dialkyne or a protected
tetraalkyne. Following deprotection to the free terminal
alkynes, a multi-CuAAC reaction with an azide bearing cRGD
peptide, similar to that reported by Liskamp et al.,34 should
furnish multimeric cRGD substrates. The synthesis of the pro-
tected alkynes and halogenated 2-iodo-nucleosides is summar-
ised in Schemes 2 and 3 respectively.
The dendrimeric core was prepared by dialkylation of
methyl 3,5-dihydroxybenzoate 9 with propargyl bromide
(Scheme 2).34 The acetylenes of the newly installed propargylic
ethers were then silylated to furnish ester 10. Ester 10 was
then reduced to the corresponding benzylic alcohol and peri-
odinane oxidation36 generated aldehyde 11 which was used
directly in future reductive amination reactions without
further purification. The linker was prepared by monoalkyl-
ation of tetraethylene glycol 12 with propargyl chloride. The
free hydroxyl was converted to the corresponding tosyl ester
and then nucleophilic displacement by azide gave the corres-
ponding azido-PEG. Reduction under Staudinger conditions37
gave amine 14. With both aldehyde 11 and amine 14 in
hand, attention turned to coupling the linker to the multi-
meric core.
The reductive amination after condensation of amine 14
with aldehyde 1138 generated both the mono- and di-alkylated
products 15 and 16. Separation of the two products by column
chromatography gave the di-alkyne linker-core assembly 15 in
35% yield (based on aldehyde 11), while the terta-alkyne
linker-core assembly 16 was formed in 21% yield (based on
aldehyde 11).
With these linker-core assemblies in hand, attention turned
to the synthesis of the iodinated coupling partners. 2-Iodo-
adenosine 17,5 was treated with thionyl chloride in pyridine,
followed by ammonia in aqueous methanol to furnish the
5′-chloro-5′-deoxy adenosine 18, as shown in Scheme 3.39 For
the synthesis of the fluorinated nucleoside, 2-iodoadenosine
17 was protected as its 2′,3′-acetonide 19 before being fluori-
nated by the action of TsF and TBAF in refluxing THF.
Deprotection to generate 20 was achieved in good yield with
catalytic anhydrous TsOH in refluxing MeOH.40
Sonogashira couplings41–43 of the halogenated 2-iodo-
nucleosides 18 and 20 with acetylenes 15 and 16 were now
Scheme 5 A. Synthesis of ClDEA-PEG-(RGD)2 30 and FDEA-PEG-(RGD)2 31. B. Synthesis of ClDEA-PEG-(RGD)4 32 and FDEA-PEG-(RGD)4 33.
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explored. 5′-Chloro-5′-deoxy-2-iodoadenosine 18 was added to
an excess of either alkyne 15 or 16 in dry, degassed DMF, in
the presence of Pd(PPh3)2Cl2 (10 mol%), CuI, and triethyl-
amine. TLC and LC-MS was used to monitoring the formation
of coupled products 21 and 25 (Scheme 4).
Coupled di-alkyne 21 and tetra-25 were subject to column
chromatography before fluoride-based deprotection of the silyl
groups using 3HF·Et3N in methanol. The products 22 and 26
were each passed through a plug of silica gel, then through a
C18 reverse phase cartridge, before being purified by semi-
preparative HPLC to give analytically pure samples of ClDEA-
PEG-(CuCH)2 22 and ClDEA-PEG-(CuCH)4 26 for CuAAC reac-
tions. Following a similar protocol, FDEA-PEG-(CuCH)2 24
and FDEA-PEG-(CuCH)4 28 were prepared and purified by
semi-preparative HPLC.
It became a focus to ‘click’ the multimeric alkynes to the
cRGD peptides in aqueous CuAAC reactions with c(RGDfK[N3])
29 as illustrated in Scheme 5A. The reactions were conducted
with CuSO4·TBTA (TBTA = tris(benzyltriazolylmethyl)amine
44)
and sodium ascorbate as the catalyst, and were monitored by
HPLC. The triazole products were trapped on a C18 cartridge,
and eluted with MeCN/water mixture and purified by semi-
preparative HPLC. This gave samples of ClDEA-PEG-(RGD)2 30
(1.8 mg, 78% yield) and FDEA-PEG-(RGD)2 31 (0.67 mg, 27%
yield), the integrity of which was supported by MALDI-TOF MS
analyses (see ESI†). The fluorinated analogue, FDEA-PEG-
(RGD)2 31, was required as a standard for assessing aﬃnity to
targets.
ClDEA-PEG-(CuCH)4 26 was found to be poorly soluble
in water and the CuAAC reaction with c(RGDfK[N3]) 29
Fig. 1 A. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)2 30 to FDEA-PEG-(RGD)2 31. B. HPLC time course (220 nm) of incubation of
ClDEA-PEG-(RGD)2 30, blue, (tR = 12.2 min) with the ﬂuorinase, showing samples taken every 0.5 h over 4 h. A new peak was evident at tR = 8.2 min,
red, identiﬁed as FDEA-PEG-(RGD)2 31. Summed mass spectrum (m/z = 400–1000) of the LC-MS peaks corresponding to the tetrameric species
from a sample taken at C. t = 0 h, showing peaks corresponding to multiply charged species of ClDEA-PEG-(RGD)2 30, and at D. t = 4 h, showing
peaks corresponding to multiply charged species of FDEA-PEG-(RGD)2 31.
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(Scheme 5B) was sluggish, but the use of 50 : 50 DMSO : water
as a reaction solvent led to complete conversion within
70 minutes. The reaction product was trapped on a C18 car-
tridge, and was washed with water to remove residual DMSO,
and then the product was eluted with MeCN : water mixtures.
Purification by semi-preparative HPLC gave ClDEA-PEG-(RGD)4
32 (1.4 mg, 70% yield), the integrity of which was confirmed
by MALDI–TOF MS (see ESI†). The tetra-acetylene, FDEA-PEG-
(CuCH)4 26 was similarly reacted in a mixture of DMSO :
water, with c(RGDfK[N3]) 29. HPLC purification gave the
desired reference compound FDEA-PEG-(RGD)4 33 (0.66 mg,
27% yield) with a m/z = 3412.6 ([M + H]+) as determined by
MALDI-TOF MS (see ESI†).
2.2. Evaluation of multimeric RGDs as substrates for the
fluorinase
With the multimeric cRGD fluorinase substrates in hand,
enzyme catalysed transhalogenation reactions were explored.
Fig. 2 A. Fluorinase catalysed transhalogenation of ClDEA-PEG-(RGD)4 32 to FDEA-PEG-(RGD)4 33. B. HPLC time course (220 nm) of incubation of
ClDEA-PEG-(RGD)4 32, green, (tR = 12.4 min) with the ﬂuorinase, showing samples taken every 0.5 h over 4 h. A new peak was evident at tR =
9.2 min, yellow, identiﬁed as FDEA-PEG-(RGD)4 33. Summed mass spectrum (m/z = 600–1000) of the LC-MS peak corresponding to the tetrameric
species of samples taken at B. t = 0 h, showing peaks corresponding to multiply charged species of ClDEA-PEG-(RGD)4 32 and at C. t = 16 h,
showing peaks corresponding to multiply charged species of FDEA-PEG-(RGD)4 22. Identical fragmentation peaks (denoted with an asterisk (*))
appear in both spectra, thought to arise from fragmentation of the adenine (C-2)–(CuCR) bond.
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ClDEA-PEG-(RGD)2 30 (40 µM) was added to a mixture of
L-SeMet (75 µM) and potassium fluoride (50 mM) in a 1 mL
volume to explore the transformation illustrated in Fig. 1A.
The reaction was initiated by addition of the fluorinase
(1 mg mL−1).
Aliquots of the reaction were removed for HPLC assay over a
4 h period in order to assess conversion. The HPLC traces in
Fig. 1B show the time-dependent appearance of the product at
tR = 8.2 min, a peak which was identified as FDEA-PEG-(RGD)2
31 by LC-MS comparison with the synthetic reference pre-
viously prepared. The mass spectra of the HPLC peaks corres-
ponding to the multimeric 5′-chloro substrates and 5′-fluoro
products are shown in Fig. 1C and D respectively. The peaks
for the product contain multiply charged ions of 31
([M + 2H]2+, [M + 3H]3+, and [M + 4H]4+ respectively), confirm-
ing its identity as FDEA-PEG-(RGD)2 31.
A series of control experiments, where the reaction was con-
ducted in the absence of either enzyme or L-SeMet, did not
result in any conversion of 30 to 31, confirming an enzyme
catalysed process. In the absence of fluoride, the consumption
of 30 was observed, however, no fluorinated product was pro-
duced. This result is consistent with the generation of a
SeSAM intermediate, which cannot be converted to product 31
in the absence of fluoride.
A similar analysis was conducted for the enzymatic reaction
with ClDEA-PEG-(RGD)4 32, as illustrated in Fig. 2A. ClDEA-
PEG-(RGD)4 32 (20 µM) was added to a mixture of L-SeMet
(75 µM) and potassium fluoride (50 mM), in a total volume of
1 mL. The reaction was initiated by the addition of the fluori-
nase (1 mg mL−1) and monitored over 4 h. The resultant HPLC
profile (Fig. 2B) indicated that 32 was consumed, while a new
peak, at tR = 9.2 min, steadily increased throughout the assay.
The retention time of this new peak was identical to that of
synthetic FDEA-PEG-(RGD)4 33, and its identity was further
confirmed by LC-MS.
Mass spectra the tetrameric substrate and product are
shown in Fig. 2C and D respectively. In the sample analysed at
t = 0 h (Fig. 2C), peaks corresponding to multiply charged
species of ClDEA-PEG-(RGD)4 32 are observed at m/z = 858.9
([M + 4H]4+) and 687.2 ([M + 5H]5+). In the sample analysed
after an extended 16 h reaction (Fig. 2D), peaks at m/z = 854.8
([M + 4H]4+) and 683.8 ([M + 5H]5+) are clearly observed. The
presence of these ions is consistent with the formation of
FDEA-PEG-(RGD)4 33 as the product of enzymatic
transhalogenation.
Tolerance of the fluorinase to these large multimeric
peptides suggests that the C-2 position of a chlorinated
nucleoside represents a site for the attachment of a diverse
range of peptide cargos for use in enzymatic fluorination.
The constructs explored here consist of 10 and 20 amino
acids, and they were eﬃciently fluorinated under neutral
aqueous conditions. With the knowledge that the multimeric
constructs were suitable substrates for fluorinase catalysed
transhalogenation, it was of interest to evaluate the
eﬀect the multiple RGD motifs on binding aﬃnity to αVβ3
integrin.
2.3. Binding aﬃnities of RGD multimers to immobilised
αVβ3 integrin
The binding aﬃnities of the fluorinated multimers 31 and 33
to αVβ3 integrin were determined by their ability to displace a
biotin-labelled cRGD peptide from immobilised αVβ3 integrin
in an ELISA assay.45 The data are shown in Table 1 including
the IC50 values of some reference peptides.
5,6 The ELISA data
indicate that for this series the multimers have a progressively
higher integrin aﬃnity (lower IC50) as the number of cRGD
ligands increases e.g., monomeric 8 (IC50 = 74 nM), dimeric 31
(IC50 = 60 nM) and tetrameric 33 (IC50 = 24 nM). The IC50
values measured for the multimeric constructs are also lower
than the parent azido-peptide 29 (IC50 = 90 nM) and the multi-
meric cRGD compounds have significantly lower IC50 values
compared with reference compounds containing linear RGD-
containing peptides.
Going from one to two cRGD motifs resulted in a marginal
increase in binding aﬃnity however progression to a tetramer
showed a significant decrease in IC50 and gave a compound
with the highest aﬃnity of those tested. The linker between
the two or four cRGD units is not so extended and steric con-
straints will likely prevent simultaneous multivalent binding
of cRGDs to more than one surface site. Instead the increased
aﬃnity is most likely due to an increased eﬀective molarity at
the surface.46 Some multimeric constructs reported in the lit-
erature have IC50 values in the 1–100 nM range,
24 similar to
this study although a direct comparison of diﬀerent assays
and dissimilar peptide motifs make accurate comparison
diﬃcult.
2.4. Enzymatic radiolabelling of multimers with fluorine-18
The ability of the fluorinase to employ these large peptide
assemblies of 10 or 20 amino acids as substrates opened up
prospects of labelling these peptides with [18F]fluoride for
PET. Radiolabelling trials of ClDEA-PEG-(RGD)2 30 (0.04 mM)
was initially investigated using similar reaction conditions to
the assays described with [19F]fluoride, but with an aqueous
[18F]fluoride solution generated on the cyclotron. The enzyme
Table 1 IC50 values of selected RGD-containing peptides measured as
the ability to compete with c(RGDfK[PEG-PEG-biotin]) for binding to
immobilised αVβ3 integrin. Results are the average ± standard error (s.e.)
from three independent experiments, each performed in triplicate. Q is
the normalised aﬃnity of the peptides, referenced to GRGDSPK
Compound IC50 ± s.e./nM Q
RGDa 8560 ± 2240 4.019
GRGDSPKa 2130 ± 410 1.000
c(RGDfK[N3]) 29
a 90 ± 10 0.042
FDEA-cRGDa 330 ± 30 0.155
FDEA-TEG-cRGD 8a 74 ± 16 0.033
FDEA-PEG-(cRGD)2 31 60 ± 13 0.027
FDEA-PEG-(cRGD)4 33 24 ± 18 0.011
a Aﬃnities for these constructs were previously reported, and were
measured using an identical assay.
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concentration was increased from 1 mg mL−1 (29 µM) to
10 mg mL−1 (290 µM), as it had previously been shown that
high enzyme concentrations improves conversions in radio-
labelling experiments.47 Notably [18F]fluoride ion concentrations
are necessarily very low in the pico-molar range. Radiochemi-
cal incorporations (RCI) were found to be low under these con-
ditions, and only traces of the product, [18F]FDEA-PEG-(RGD)2
[18F]-31 were observed by radio-HPLC. Optimisation trials were
carried out with ClDA 4 to [18F]FDA [18F]-2 as a substrate, and
the data suggest that an important factor for improving radio-
chemical incorporations is substrate concentration. A RCI of
greater than 90% was observed when ClDA 4 was incubated at
a concentration of 0.6 mM, compared with a 10% RCI at
0.04 mM (see ESI†).
Fig. 3 A. Reaction scheme and resultant isocratic HPLC radioactivity trace of an experiment where ClDEA-PEG-(RGD)2 30 (0.3 mM) was freeze dried with
the ﬂuorinase (20 mg mL−1) prior to reaction. [18F]FDEA-PEG-(RGD)2 [
18F]-31 was observed at tR = 13.7 min, showing 10% RCI. B. Reaction scheme and
resultant gradient HPLC radioactivity trace of an experiment where ClDEA-PEG-(RGD)4 32 (0.3 mM) was freeze dried with the ﬂuorinase (20 mg mL
−1)
prior to reaction. [18F]FDEA-PEG-(RGD)4 [
18F]-33 was observed at tR = 10.1 min, showing 5% RCI. An additional peak was also observed at tR = 5.2 min,
identiﬁed as [18F]FDA [18F]-2, produced due to the presence of residual SAM 1 co-puriﬁed with the ﬂuorinase.48 The peak is also present for ClDEA-PEG-
(RGD)2 30 labelling experiments, but is not observed in A due to the HPLC conditions utilised (see ESI† for further discussion).
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By contrast, ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4
32 were found to be poorly soluble in water, and concen-
trations of 0.6 mM were not achievable in buﬀer. The upper
concentration limit for the peptides was found to be ∼0.3 mM.
ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4 32 were incu-
bated in separate experiments with L-SeMet (0.08 mM) and
[18F]fluoride in water (138 µL–160 µL, 15.2–35.4 MBq). Some
precipitation of the substrate was observed upon addition of
aqueous [18F]fluoride. The reaction mixtures were incubated at
37 °C for 30 minutes, and then the enzyme was heat denatured
and the mixture centrifuged. A sample of the clarified super-
natant from each reaction was analysed by HPLC, and the
resultant HPLC radio-chromatograms are shown in Fig. 3.
Radio-HPLC of the two reaction mixtures (Fig. 3A and B)
revealed the presence of the respective [18F]-products, along
with a broad peak (tR = 2.2 min), identified as [
18F]fluoride.49
The peak at tR = 13.7 min in Fig. 3A was identified as [
18F]-31
by spiking and comparison of the retention time to that of a
[19F]-reference sample. Similarly the peak at tR = 10.1 min in
Fig. 3B was identified as [18F]-33 relative to a [19F]-reference.
[18F]-FDA [18F]-2 was also observed in this experiment, which
must arise as a consequence of low levels of L-AdoMet (SAM)
bound to the enzyme and residual from the purification
process. This outcome only arose in the reactions of low con-
version. Reactions were also conducted with the addition of
DMSO 1% (v/v) as a co-solvent, however this did not improve
the radiochemical conversions and extending the reaction
time or increasing the concentration of L-SeMet had no signifi-
cant eﬀect. Therefore despite the eﬃcient conversions
observed in the “cold” experiments at high [19F]fluoride ion
concentrations, low [18F]fluoride concentrations require to be
compensated for by high substrate concentrations, and this
limited the eﬃciency of the radiolabelled experiments.
3. Conclusions
Enzymatic transhalogenations using the fluorinase was
explored with relatively complex di- and tetra-cRGD constructs.
This exploited the previously identified substrate tolerance at
C-2 of the adenine base in the substrate motif. The multimeric
assemblies, ClDEA-PEG-(RGD)2 30 and ClDEA-PEG-(RGD)4 32,
were assessed as fluorinase substrates and both were found to
undergo eﬃcient enzyme-catalysed transhalogenations. The
multimers also showed higher aﬃnities to immobilised αVβ3
integrins, which opened up the prospect of using them as
cancer imaging agents in [18F]-radiolabelled form. This proved
only partially successful due to the relatively poor solubility of
the multimeric constructs and low [18F]-fluoride concen-
trations. It follows that the development of this approach to
larger peptides or proteins will depend on using more highly
soluble peptide substrates in buﬀer. The peptides used here
are ‘click’ derived with low solubility, however the approach
should prove more useful with natural peptides and antibodies
which have evolved high water solubility.
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